Pancreatic metastasis refers to the hematogenous or lymphatic spread of malignant cells from another primary tumor to the pancreas. Renal cell carcinoma (RCC) is the most common source (60-70%); lung, breast, melanoma, and colorectal carcinomas are other frequent primaries. Pancreatic metastases account for 2-5% of all pancreatic malignancies. RCC metastases can appear years to decades after the primary tumor (late metastasis phenomenon). They may be solitary, making differentiation from pancreatic ductal adenocarcinoma critical since surgical resection improves survival.
Age Range
40-80
Peak Age
60
Gender
Equal
Prevalence
Uncommon
The pathophysiology of pancreatic metastases varies with the primary tumor biology. RCC metastases demonstrate intense arterial phase enhancement due to their rich vascular architecture — this hypervascularity reflects RCC's VEGF-rich tumor biology and mimics pancreatic neuroendocrine tumors. Lung and breast metastases are typically hypovascular and may resemble ductal adenocarcinoma. Melanoma metastases may show intrinsic T1 hyperintensity on MRI — this results from the paramagnetic properties of melanin pigment. The pancreas is a favorable target organ for hematogenous spread due to its rich blood supply and retroperitoneal location. The late metastasis phenomenon (especially 10-20 years after RCC) is explained by the dormant micrometastasis theory.
A well-defined pancreatic mass with intense arterial phase enhancement in a patient with known RCC history is the most specific finding combination for pancreatic metastasis. 60-70% of RCC metastases show this hypervascular pattern, mimicking neuroendocrine tumor.
RCC-derived pancreatic metastases demonstrate intense, homogeneous enhancement in the arterial phase. This enhancement pattern mimics pancreatic neuroendocrine tumor (pNET) and is clearly distinguishable from normal pancreatic parenchyma.
Report Sentence
A well-defined lesion demonstrating intense arterial phase enhancement is identified in the pancreas, and in the context of known RCC history, metastasis should be the primary consideration.
In the portal venous phase, RCC metastases may show persistent enhancement or mild washout. Hypovascular metastases (lung, breast) remain hypodense in the portal phase — similar to ductal adenocarcinoma.
Report Sentence
Persistent enhancement of the lesion is observed in the portal venous phase, consistent with hypervascular metastasis.
On non-contrast CT, pancreatic metastases typically appear as well-defined masses isodense or slightly hypodense to pancreatic parenchyma. Heterogeneous attenuation may be seen in necrotic or hemorrhagic metastases.
Report Sentence
On non-contrast CT, a well-defined mass isodense to pancreatic parenchyma is identified in the pancreas.
On T1-weighted MRI, metastases are typically hypointense relative to pancreatic parenchyma. Important exception: melanoma metastases may show T1 hyperintense signal due to melanin pigment — this finding is highly characteristic for melanoma.
Report Sentence
Hyperintense signal is observed in the pancreatic mass on T1-weighted sequences, which should be evaluated for melanoma metastasis.
On T2-weighted MRI, metastases show variable signal depending on the primary tumor. RCC metastases typically demonstrate moderate-to-high signal intensity, while mucinous metastases may be markedly hyperintense and desmoplastic metastases may be hypointense.
Report Sentence
Moderate-to-high signal intensity is observed in the pancreatic mass on T2-weighted sequences, consistent with vascular-rich metastasis.
On DWI, metastases typically show diffusion restriction — due to high cellularity. ADC values are low, supporting malignancy. However, this finding is non-specific and does not differentiate from other pancreatic malignancies.
Report Sentence
Diffusion restriction is observed in the pancreatic mass on DWI, consistent with malignancy.
On ultrasonography, pancreatic metastases typically appear as well-defined, hypoechoic solid masses. In large lesions, heterogeneous echo pattern may be seen due to internal necrosis. US sensitivity is limited and confirmation with CT/MRI is required.
Report Sentence
A well-defined, hypoechoic solid mass is identified in the pancreas, and further imaging evaluation is recommended.
On FDG PET-CT, pancreatic metastases are typically FDG-avid with increased metabolic activity. PET-CT plays a critical role in evaluating simultaneous extra-pancreatic metastases and primary tumor activity. RCC metastases may show variable FDG uptake.
Report Sentence
Increased FDG uptake is observed in the pancreatic mass on PET-CT, consistent with metastatic disease.
Criteria
Known RCC history, intense arterial phase enhancement, well-defined, may show washout
Distinct Features
Most common type (60-70%). Solitary or multiple. Mimics pNET. May appear 10-20 years after primary RCC. Long-term survival possible with surgical resection.
Criteria
Known lung or breast carcinoma, hypovascular in arterial phase, hypodense in portal phase
Distinct Features
Mimics ductal adenocarcinoma. Ductal obstruction is rare (unlike adenocarcinoma). Well-defined margin and absence of ductal invasion are distinguishing clues.
Criteria
Known melanoma history, T1 hyperintense signal (melanin), usually multiple
Distinct Features
T1 hyperintensity due to paramagnetic properties of melanin pigment is pathognomonic. This finding may be absent in amelanotic melanoma. Hemorrhagic component may also contribute to T1 hyperintensity.
Criteria
2 or more lesions in the pancreas, known primary malignancy, similar enhancement pattern
Distinct Features
Seen in 20-45% of patients. Multiple lesions strengthen the diagnosis of metastasis. Ductal adenocarcinoma is rarely multifocal. All lesions show similar enhancement pattern.
Distinguishing Feature
pNET can also be hypervascular in the arterial phase but is usually solitary, may be accompanied by pancreatic hormone syndrome (insulinoma/gastrinoma), and there is no history of extra-pancreatic malignancy. Chromogranin A and somatostatin receptor scintigraphy (SRS) are distinguishing.
Distinguishing Feature
Ductal adenocarcinoma is hypovascular (hypodense in arterial phase), ill-defined, characterized by ductal obstruction and upstream atrophy. Metastases are typically well-defined and do not cause ductal dilatation. The 'double duct sign' is typical for adenocarcinoma.
Distinguishing Feature
SPN typically occurs in young women, large encapsulated mass with solid-cystic components, contains hemorrhagic areas (hyperintense on T1). Metastasis is usually associated with older age and known primary malignancy history.
Distinguishing Feature
Pancreatic lymphoma is typically a homogeneous, mildly hypodense mass that does not cause luminal narrowing despite vascular encasement ('vessel encasement without stenosis'). Metastasis does not compress or invade vessels. Systemic lymphoma findings (LAP, splenomegaly) support lymphoma.
Urgency
urgentManagement
surgicalBiopsy
NeededFollow-up
specialist-referralPancreatic metastasis diagnosis determines treatment planning based on the nature of the primary tumor. Surgical resection (pancreatectomy) for RCC metastases can provide long-term survival — 5-year survival 30-50%. Resection is especially indicated for solitary metastases. In multiple or widespread metastatic disease, systemic therapy (tyrosine kinase inhibitors, immunotherapy) is preferred. Biopsy is needed for histological confirmation and primary tumor type determination — especially if the primary is unknown.
Pancreatic metastases usually present late and often years after the primary diagnosis. Surgical resection of isolated pancreatic metastasis may improve survival, especially for RCC-origin metastases. EUS-FNA is used to confirm the diagnosis.